Clinical Trial Update: Study to Evaluate the Safety and Efficacy of ATYR1923 (Efzofitimod) In Participants With Severe Pneumonia Related to COVID-19 [Phase 2]

View source ↗

Summary

Phase 2 study evaluating safety and efficacy of Efzofitimod (ATYR1923) in patients with severe COVID-19 pneumonia has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pneumonia Due to Sars-cov-2 Infection

Drugs mentioned

• Efzofitimod (efzofitimod)

Snippet

Sponsor: aTyr Pharma, Inc. | Conditions: SARS-CoV-2 (COVID-19) Severe Pneumonia | Phase 2 | Status: COMPLETED | Results posted: 2023-08-18